← Database
M&A

ATOS MEDICAL

Acquired by

COLOPLAST

SWEDEN Life Sciences EV [1b EUR - 100b EUR] 11/2021

Target

ATOS MEDICAL

Acquirer

COLOPLAST

Context

Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market. The rationale for the acquisition is highly strategic for Coloplast, as it adds a new chronic care segment to its existing portfolio. Atos Medical’s business model is a perfect fit for Coloplast’s "Chronic Care" strategy, characterized by high-recurring revenue from medical consumables and a strong direct-to-consumer orientation. The merger allows Coloplast to leverage Atos Medical’s industry-leading margins and unique patient-reach capabilities while providing Atos with Coloplast’s massive global infrastructure to further accelerate expansion in emerging and under-penetrated markets.

Target

Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2021
LOGIN
LOGIN
LOGIN
2020
LOGIN
LOGIN
LOGIN

Other operations with ATOS MEDICAL

DateAcquirerTargetCountrySectorDeal Context
06/2016PAI PARTNERSATOS MEDICALSWEDEN
Life Sciences

PAI Partners has entered into a definitive agreement to acquire 100% of Atos Medical from EQT. This secondary LBO represents the 10th investment of the PAI Europe VI fund and marks the exit of EQT, which had overseen a period where the company doubled in size within five years. The current management team, led by CEO Claus Bjerre, remains in place to lead the next phase of the company's development under PAI's sponsorship. The strategic rationale for the acquisition is centered on the underpenetrated nature of the global laryngectomy market and the scalability of Atos Medical's direct-to-consumer model. PAI intends to leverage its healthcare sector capabilities to accelerate the company's transformational strategy, focusing on increased R&D investment and a broader global sales footprint. The deal is underpinned by the target's exceptional financial performance, including a 30% revenue growth in 2015 and industry-leading margins.